Dancing with chemical formulae of antivirals: A panoramic view (Part 2)

Biochemical Pharmacology

Volumn 86, Issue 10, 2013, Pages 1397-1410

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

CMX 001; Direct acting antivirals (DAAs); Favipiravir; Helicase primase inhibitors (HPIs); HIV protease inhibitors (PIs); Integrase inhibitors (INIs); Neuraminidase inhibitors; Norovirus; Sofosbuvir

Indexed keywords

ACICLOVIR; AMPRENAVIR; ANTIVIRUS AGENT; ASUNAPREVIR; ATAZANAVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; COBICISTAT; DACLATASVIR; DARUNAVIR; DOLUTEGRAVIR; ELVITEGRAVIR; FAVIPIRAVIR; FOSAMPRENAVIR; INDINAVIR; LANINAMIVIR; LANINAMIVIR OCTANOATE; LEDIPASVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; OSELTAMIVIR; PEGINTERFERON; PERAMIVIR; PROTEINASE INHIBITOR; RALTEGRAVIR; RIBAVIRIN; SAQUINAVIR; SOFOSBUVIR; TIPRANAVIR; ZANAMIVIR;

2009 H1N1 INFLUENZA; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INFLUENZA; INFLUENZA VIRUS A H5N1; INSULIN RESISTANCE; MONOTHERAPY; NONHUMAN; POXVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; RNA VIRUS; SINGLE DRUG DOSE; TREATMENT DURATION; VIRUS LOAD;

EID: 84887084522     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.09.010     Document Type: Note

References (128)

1. E. De Clercq Dancing with chemical formulae of antivirals: a personal account Biochem Pharmacol 86 2013 711 725
2. R.W. Sidwell, J.H. Huffman, G.P. Khare, L.B. Allen, J.T. Witkowski, and R.K. Robins Broad-spectrum antiviral activity of Virazole: 1-beta-d- ribofuranosyl-1,2,4-triazole-3-carboxamide Science 177 1972 705 706
3. D.G. Streeter, J.T. Witkowski, G.P. Khare, R.W. Sidwell, R.J. Bauer, and R.K. Robins Mechanism of action of 1-β-d-ribofuranosyl-1,2,4-triazole-3- carboxamide (Virazole), a new broad-spectrum antiviral agent PNAS 70 1973 1174 1178
4. B. Eriksson, E. Helgstrand, N.G. Johansson, A. Larsson, A. Misiorny, and J.O. Norén Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate Antimicrob Agents Chemother 11 1977 946 951 (Pubitemid 8129651)
5. Y. Furuta, K. Takahashi, Y. Fukuda, M. Kuno, T. Kamiyama, and K. Kozaki In vitro and in vivo activities of anti-influenza virus compound T-705 Antimicrob Agents Chemother 46 2002 977 981 (Pubitemid 34260339)
6. Y. Furuta, K. Takahashi, M. Kuno-Maekawa, H. Sangawa, S. Uehara, and K. Kozaki Mechanism of action of T-705 against influenza virus Antimicrob Agents Chemother 49 2005 981 986 (Pubitemid 40327713)
7. R.W. Sidwell, D.L. Barnard, C.W. Day, D.F. Smee, K.W. Bailey, and M.H. Wong Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice Antimicrob Agents Chemother 51 2007 845 851 (Pubitemid 46355265)
8. M. Kiso, K. Takahashi, Y. Sakai-Tagawa, K. Shinya, S. Sakabe, and Q.M. Le T-705 (favipiravir) activity against lethal H5N1 influenza A viruses PNAS 107 2010 882 887
9. K. Sleeman, V.P. Mishin, V.M. Deyde, Y. Furuta, A.I. Klimov, and L.V. Gubareva In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses Antimicrob Agents Chemother 54 2010 2517 2524
10. E.B. Tarbet, M. Maekawa, Y. Furuta, Y.S. Babu, J.D. Morrey, and D.F. Smee Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice Antiviral Res 94 2012 103 110
11. B.B. Gowen, M.H. Wong, K.H. Jung, A.B. Sanders, M. Mendenhall, and K.W. Bailey In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections Antimicrob Agents Chemother 51 2007 3168 3176 (Pubitemid 350067524)
12. M. Mendenhall, A. Russell, T. Juelich, E.L. Messina, D.F. Smee, and A.N. Freiberg T-705 (favipiravir) inhibition of arenavirus replication in cell culture Antimicrob Agents Chemother 55 2011 782 787
13. B.B. Gowen, D.F. Smee, M.H. Wong, J.O. Hall, K.H. Jung, and K.W. Bailey Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin PLoS One 3 2008 e3725
14. K.K. Buys, K.H. Jung, D.F. Smee, Y. Furuta, and B.B. Gowen Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir Antivir Chem Chemother 21 2011 193 200
15. S. Crotty, C.E. Cameron, and R. Andino RNA virus error catastrophe: direct molecular test by using ribavirin PNAS 98 2001 6895 6900 (Pubitemid 32538313)
16. T. Baranovich, S.S. Wong, J. Armstrong, H. Marjuki, R.J. Webby, and R.G. Webster T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro J Virol 87 2013 3741 3751
17. E. De Clercq Antiviral agents active against influenza A viruses Nat Rev Drug Discov 5 2006 1015 1025 (Pubitemid 44835128)
18. J. Hsu, N. Santesso, R. Mustafa, J. Brozek, Y.L. Chen, and J.P. Hopkins Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies Ann Intern Med 156 2012 512 524
19. J.H. Kim, R. Resende, T. Wennekes, H.M. Chen, N. Bance, and S. Buchini Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity Science 340 2013 71 75
20. E.A. Govorkova, T. Baranovich, P. Seiler, J. Armstrong, A. Burnham, and Y. Guan Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring Antiviral Res 98 2013 297 304
21. K.M. Chan-Tack, A. Gao, A.C. Himaya, E.G. Thompson, M.E. Singer, and T.M. Uyeki Clinical experience with intravenous zanamivir under an emergency investigational new drug program in the United States J Infect Dis 207 2013 196 198
22. P.L. Fraaij, E. van der Vries, M.F. Beersma, A. Riezebos-Brilman, H.G. Niesters, and A.A. van der Eijk Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection J Infect Dis 204 2011 777 782
23. A.K. Weight, J. Haldar, L. Alvarez de Cienfuegos, L.V. Gubareva, T.M. Tumpey, and J. Chen Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza a virus J Pharm Sci 100 2011 831 835
24. C.M. Lee, A.K. Weight, J. Haldar, L. Wang, A.M. Klibanov, and J. Chen Polymer-attached zanamivir inhibits synergistically both early and late stages of influenza virus infection PNAS 109 2012 20385 20390
25. M.M. Kaminski, A. Ohnemus, P. Staeheli, and D. Rubbenstroth Pandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model J Virol 87 2013 1912 1915
26. A.C. Hurt, J.K. Holien, M. Parker, A. Kelso, and I.G. Barr Zanamivir-resistant influenza viruses with a novel neuraminidase mutation J Virol 83 2009 10366 10373
27. E. van der Vries, F.F. Stelma, and C.A. Boucher Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus N Engl J Med 363 2010 1381 1382
28. A. Moscona Global transmission of oseltamivir-resistant influenza N Engl J Med 360 2009 953 955
29. H.L. Yen, N.A. Ilyushina, R. Salomon, E. Hoffmann, R.G. Webster, and E.A. Govorkova Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo J Virol 81 2007 12418 12426 (Pubitemid 350085855)
30. M.G. Ison Clinical use of approved influenza antivirals: therapy and prophylaxis Influenza Other Respi Viruses 7 Suppl 1 2013 7 13
31. H.T. Nguyen, A.M. Fry, and L.V. Gubareva Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods Antivir Ther 17 2012 159 173
32. J.L. McKimm-Breschkin Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance Influenza Other Respi Viruses 7 Suppl 1 2013 25 36
33. J.L. McKimm-Breschkin, C. Rootes, P.G. Mohr, S. Barrett, and V.A. Streltsov In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir J Antimicrob Chemother 67 2012 1874 1883
34. A. Pizzorno, Y. Abed, X. Bouhy, E. Beaulieu, C. Mallett, and R. Russell Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus Antimicrob Agents Chemother 56 2012 1208 1214
35. Y. Abed, A. Pizzorno, and G. Boivin Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation Antimicrob Agents Chemother 56 2012 4375 4380
36. M. Kitano, M. Kodama, Y. Itoh, T. Kanazu, M. Kobayashi, and R. Yoshida Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice Antimicrob Agents Chemother 57 2013 2286 2294
37. N. Sugaya, S. Kohno, T. Ishibashi, T. Wajima, and T. Takahashi Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection Antimicrob Agents Chemother 56 2012 369 377
38. A. Sorbello, S.C. Jones, W. Carter, K. Struble, R. Boucher, and M. Truffa Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus Clin Infect Dis 55 2012 1 7
39. K. Koyama, D. Nakai, M. Takahashi, N. Nakai, N. Kobayashi, and T. Imai Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate Drug Metab Dispos 41 2013 180 187
40. H. Ishizuka, K. Toyama, S. Yoshiba, H. Okabe, and H. Furuie Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers Antimicrob Agents Chemother 56 2012 3873 3878
41. Y. Katsumi, O. Otabe, F. Matsui, S. Kidowaki, A. Mibayashi, and Y. Tsuma Effect of a single inhalation of laninamivir octanoate in children with influenza Pediatrics 129 2012 e1431 e1436
42. M.J. Sofia, D. Bao, W. Chang, J. Du, D. Nagarathnam, and S. Rachakonda Discovery of a β-d-2′-deoxy-2′-α-fluoro-2′-β- C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus J Med Chem 53 2010 7202 7218
43. E. Murakami, T. Tolstykh, H. Bao, C. Niu, H.M. Steuer, and D. Bao Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977 J Biol Chem 285 2010 34337 34347
44. A.M. Lam, E. Murakami, C. Espiritu, H.M. Steuer, C. Niu, and M. Keilman PSI-7851, a pronucleotide of beta-d-2′-deoxy-2′-fluoro-2′-C- methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication Antimicrob Agents Chemother 54 2010 3187 3196
45. E.J. Gane, C.A. Stedman, R.H. Hyland, X. Ding, E. Svarovskaia, and W.T. Symonds Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N Engl J Med 368 2013 34 44
46. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, and S.C. Gordon Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
47. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, E.M. Yoshida, M. Rodriguez-Torres, M.S. Sulkowski POSITRON Study; FUSION Study Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
48. R.E. Nettles, M. Gao, M. Bifano, E. Chung, A. Persson, and T.C. Marbury Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1 Hepatology 54 2011 1956 1965
49. J. Guedj, H. Dahari, L. Rong, N.D. Sansone, R.E. Nettles, and S.J. Cotler Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life PNAS 110 2013 3991 3996
50. A. Suk-Fong Lok HCV NS5A inhibitors in development Clin Liver Dis 17 2013 111 121
51. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, and R.A. Fridell Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
52. C. Wang, H. Huang, L. Valera, J.H. Sun, D.R. O'Boyle 2nd, and P.T. Nower Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052 Antimicrob Agents Chemother 56 2012 1350 1358
53. P.J. Lim, U. Chatterji, D. Cordek, S.D. Sharma, J.A. Garcia-Rivera, and C.E. Cameron Correlation between NS5A dimerization and hepatitis C virus replication J Biol Chem 287 2012 30861 30873
54. J. Shi, L. Zhou, F. Amblard, D.R. Bobeck, H. Zhang, and P. Liu Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors Bioorg Med Chem Lett 22 2012 3488 3491
55. F. Amblard, H. Zhang, L. Zhou, J. Shi, D.R. Bobeck, and J.H. Nettles Synthesis and evaluation of non-dimeric HCV NS5A inhibitors Bioorg Med Chem Lett 23 2013 2031 2034
56. R.T. Chung A watershed moment in the treatment of hepatitis C N Engl J Med 366 2012 273 275
57. K. Chayama, S. Takahashi, J. Toyota, Y. Karino, K. Ikeda, and H. Ishikawa Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders Hepatology 55 2012 742 748
58. J.M. Gottwein, S.B. Jensen, Y.P. Li, L. Ghanem, T.K. Scheel, and S.B. Serre Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses Antimicrob Agents Chemother 57 2013 1291 1303
59. S. Pol, R.H. Ghalib, V.K. Rustgi, C. Martorell, G.T. Everson, and H.A. Tatum Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial Lancet Infect Dis 12 2012 671 677
60. L.A. Pelosi, S. Voss, M. Liu, M. Gao, and J.A. Lemm Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir Antimicrob Agents Chemother 56 2012 5230 5239
61. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, and R. Ghalib Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
62. E.J. Lawitz, D. Gruener, J.M. Hill, T. Marbury, L. Moorehead, and A. Mathias A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C J Hepatol 57 2012 24 31
63. E. Lawitz, D. Gruener, J. Hill, T. Marbury, S. Komjathy, and M. DeMicco Three-day, dose-ranging study of the HCV NS5A inhibitor GS-5885 J Hepatol 54 2011 S481 S482
64. G.T. Everson, E. Lawitz, A.J. Thompson, M.S. Sulkowski, Y. Zhu, and D.M. Brainard The NS5A inhibitor GS-5885 is safe and well-tolerated in over 1000 patients treated in phase 2 studies Hepatology 56 2012 572A
65. A.M. Wensing, N.M. van Maarseveen, and M. Nijhuis Fifteen years of HIV protease inhibitors: raising the barrier to resistance Antiviral Res 85 2010 59 74
66. Y. Koh, H. Nakata, K. Maeda, H. Ogata, G. Bilcer, and T. Devasamudram Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro Antimicrob Agents Chemother 47 2003 3123 3129 (Pubitemid 37229567)
67. A.K. Ghosh, D.D. Anderson, I.T. Weber, and H. Mitsuya Enhancing protein backbone binding - a fruitful concept for combating drug-resistant HIV Angew Chem Int Ed Engl 51 2012 1778 1802
68. S. De Meyer, H. Azijn, D. Surleraux, D. Jochmans, A. Tahri, and R. Pauwels TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates Antimicrob Agents Chemother 49 2005 2314 2321 (Pubitemid 40734460)
69. L. Menéndez-Arias Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments Antiviral Res 98 2013 93 120
70. M.W. Hull, and J.S. Montaner Ritonavir-boosted protease inhibitors in HIV therapy Ann Med 43 2011 375 388
71. C.J. Achenbach, K.M. Darin, R.L. Murphy, and C. Katlama Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults Future Virol 6 2011 157 177
72. F. Pulido, M. Matarranz, V. Rodríguez-Rivera, S. Fiorante, and A. Hernando Boosted protease inhibitor monotherapy: what have we learnt after seven years of research? AIDS Rev 12 2010 127 134
73. F. Raffi, and M.A. Wainberg Multiple choices for HIV therapy with integrase strand transfer inhibitors Retrovirology 9 2012 110
74. M.A. Wainberg, T. Mesplède, and P.K. Quashie The development of novel HIV integrase inhibitors and the problem of drug resistance Curr Opin Virol 2 2012 656 662
75. K.E. Squires, L.G. Bekker, J.J. Eron, B. Cheng, J.K. Rockstroh, F. Marquez REALMRK Investigators Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study AIDS Res Hum Retroviruses 29 2013 859 870
76. R. Elion, J.M. Molina, J. Ramón Arribas López, D. Cooper, F. Maggiolo, E. Wilkins for the Study 145 Team A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results J Acquir Immune Defic Syndr 63 2013 494 497
77. J.M. Molina, A. Lamarca, J. Andrade-Villanueva, B. Clotet, N. Clumeck, Y.P. Liu Study 145 Team Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study Lancet Infect Dis 12 2012 27 35
78. M.E. Abram, R.M. Hluhanich, D.D. Goodman, K.N. Andreatta, N.A. Margot, and L. Ye Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness Antimicrob Agents Chemother 57 2013 2654 2663
79. E. DeJesus, J.K. Rockstroh, K. Henry, J.M. Molina, J. Gathe, S. Ramanathan GS-236-0103 Study Team Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial Lancet 379 2012 2429 2438
80. P.E. Sax, E. DeJesus, A. Mills, A. Zolopa, C. Cohen, D. Wohl GS-US-236-0102 study team Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks Lancet 379 2012 2439 2448
81. A. Zolopa, P.E. Sax, E. DeJesus, A. Mills, C. Cohen, D. Wohl GS-US-236-0102 Study Team A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results J Acquir Immune Defic Syndr 63 2013 96 100
82. S.L. Karmon, and M. Markowitz Next-generation integrase inhibitors: where to after raltegravir? Drugs 73 2013 213 228
83. F. Canducci, E.R. Ceresola, E. Boeri, V. Spagnuolo, F. Cossarini, and A. Castagna Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir J Infect Dis 204 2011 1811 1815
84. P. Messiaen, A.M. Wensing, A. Fun, M. Nijhuis, N. Brusselaers, and L. Vandekerckhove Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis PLoS One 8 2013 e52562
85. F. Raffi, A. Rachlis, H.J. Stellbrink, W.D. Hardy, C. Torti, C. Orkin SPRING-2 Study Group nce-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study Lancet 381 2013 735 743
86. B.A. Desimmie, J. Demeulemeester, V. Suchaud, O. Taltynov, M. Billamboz, and C. Lion 2-Hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs), novel inhibitors of HIV integrase with a high barrier to resistance ACS Chem Biol 8 2013 1187 1194
87. M. Métifiot, K. Maddali, B.C. Johnson, S. Hare, S.J. Smith, and X.Z. Zhao Activities, crystal structures, and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase ACS Chem Biol 8 2013 209 217
88. P.E. Boehmer, and I.R. Lehman Herpes simplex virus DNA replication Annu Rev Biochem 66 1997 347 384 (Pubitemid 27274661)
89. G. Kleymann, R. Fischer, U.A. Betz, M. Hendrix, W. Bender, and U. Schneider New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease Nat Med 8 2002 392 398 (Pubitemid 34407035)
90. J.J. Crute, C.A. Grygon, K.D. Hargrave, B. Simoneau, A.M. Faucher, and G. Bolger Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease Nat Med 8 2002 386 391 (Pubitemid 34407034)
91. J.J. Crute, T. Tsurumi, L.A. Zhu, S.K. Weller, P.D. Olivo, and M.D. Challberg Herpes simplex virus 1 helicase-primase: a complex of three herpes-encoded gene products PNAS 86 1989 2186 2189 (Pubitemid 19102477)
92. F.C. Spector, L. Liang, H. Giordano, M. Sivaraja, and M.G. Peterson Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex J Virol 72 1998 6979 6987 (Pubitemid 28377824)
93. U.A. Betz, R. Fischer, G. Kleymann, M. Hendrix, and H. Rübsamen-Waigmann Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293 Antimicrob Agents Chemother 46 2002 1766 1772 (Pubitemid 34535195)
94. S. Biswas, L. Jennens, and H.J. Field The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1 Antiviral Res 75 2007 30 35 (Pubitemid 46621066)
95. S. Biswas, C. Smith, and H.J. Field Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1 J Antimicrob Chemother 60 2007 274 279 (Pubitemid 47243874)
96. S. Sukla, S. Biswas, A. Birkmann, P. Lischka, H. Zimmermann, and H.J. Field Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor J Antimicrob Chemother 65 2010 1347 1352
97. S. Biswas, G. Kleymann, M. Swift, L.S. Tiley, J. Lyall, and J. Aguirre-Hernández A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target J Antimicrob Chemother 61 2008 1044 1047 (Pubitemid 351524447)
98. H.J. Field, I. Mickleburgh, H.-L. Huang, L. Tiley, A. Wald, and H. Ruebsamen-Schaeff Sensitivity of clinical isolates to helicase-primase inhibitors and no detection of resistance mutations above background frequency Abstracts of the 25th international conference on antiviral research Sapporo, Japan, 16-29 April 2012 Abstract no. 46
99. M. Huang, K. Diem, S. Selke, A. Wald, L. Corey, and H. Ruebsamen-Schaeff No emergence of resistance under treatment with the novel HSV inhibitor AIC316 in persons with genital herpes 51st Interscience conference on antimicrobial agents and chemotherapy (ICAAC) Chicago, IL, 17-20 September 2011 presentation V-941b
100. A. Birkmann, D. McCormick, D. Kropelt, B. Timmler, S. Stoelben, and M.P. Richard Excellent efficacy and pharmacokinetics have been demonstrated in pre-clinical and phase I/II studies by AIC316, a novel drug against herpes simplex (HSV) type 1 and 2 Abstracts of the 25th international conference on antiviral research Sapporo, Japan, 16-29 April 2012 Abstract no. 48
101. M.J.M. Hitchcock, H.S. Jaffe, J.C. Martin, and R.J. Stagg Cidofovir, a new agent with potent anti-herpesvirus activity Antivir Chem Chemother 7 1996 115 127 (Pubitemid 26150100)
102. K. Geerinck, G. Lukito, R. Snoeck, R. De Vos, E. De Clercq, and Y. Vanrenterghem A case of human orf in an immunocompromised patient treated successfully with cidofovir cream J Med Virol 64 2001 543 549 (Pubitemid 32613744)
103. J.R. Beadle, W.B. Wan, S.L. Ciesla, K.A. Keith, C. Hartline, and E.R. Kern Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses J Med Chem 49 2006 2010 2015
104. K.Y. Hostetler Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate Viruses 2 2010 2213 2225
105. S.L. Ciesla, J. Trahan, W.B. Wan, J.R. Beadle, K.A. Aldern, and G.R. Painter Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney Antiviral Res 59 2003 163 171 (Pubitemid 36966748)
106. D.J. Bidanset, J.R. Beadle, W.B. Wan, K.Y. Hostetler, and E.R. Kern Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection J Infect Dis 190 2004 499 503 (Pubitemid 38982087)
107. E.R. Kern, D.J. Collins, W.B. Wan, J.R. Beadle, K.Y. Hostetler, and D.C. Quenelle Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir Antimicrob Agents Chemother 48 2004 3516 3522 (Pubitemid 39129353)
108. D.C. Quenelle, B. Lampert, D.J. Collins, T.L. Rice, G.R. Painter, and E.R. Kern Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies J Infect Dis 202 2010 1492 1499
109. M.N. Prichard, E.R. Kern, C.B. Hartline, E.R. Lanier, and D.C. Quenelle CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections Antimicrob Agents Chemother 55 2011 4728 4734
110. F.J. Bravo, D.I. Bernstein, J.R. Beadle, K.Y. Hostetler, and R.D. Cardin Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection Antimicrob Agents Chemother 55 2011 35 41
111. J. Stabenow, R.M. Buller, J. Schriewer, C. West, J.E. Sagartz, and S. Parker A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus J Virol 84 2010 3909 3920
112. S. Parker, N.G. Chen, S. Foster, H. Hartzler, E. Hembrador, and D. Hruby Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox Antiviral Res 94 2012 44 53
113. S.H. James, N.B. Price, C.B. Hartline, E.R. Lanier, and M.N. Prichard Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus Antimicrob Agents Chemother 57 2013 3321 3325
114. C. Erickson, M. Driscoll, and A. Gaspari Efficacy of intravenous cidofovir in the treatment of giant molluscum contagiosum in a patient with human immunodeficiency virus Arch Dermatol 147 2011 652 654
115. J.I. Cohen, W. Davila, M.A. Ali, S.P. Turk, E.W. Cowen, and A.F. Freeman Detection of molluscum contagiosum virus (MCV) DNA in the plasma of an immunocompromised patient and possible reduction of MCV DNA with CMX-001 J Infect Dis 205 2012 794 797
116. H. Wang, J. Chhablani, W.R. Freeman, J.R. Beadle, K.Y. Hostetler, and K. Hartmann Intraocular safety and pharmacokinetics of hexadecyloxypropyl-cidofovir (HDP-CDV) as a long-lasting intravitreal antiviral drug Invest Ophthalmol Vis Sci 52 2011 9391 9396
117. W. Painter, A. Robertson, L.C. Trost, S. Godkin, B. Lampert, and G. Painter First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses Antimicrob Agents Chemother 56 2012 2726 2734
118. D.F. Florescu, S.A. Pergam, M.N. Neely, F. Qiu, C. Johnston, and S. Way Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients Biol Blood Marrow Transplant 18 2012 731 738
119. K. Bok, and K.Y. Green Norovirus gastroenteritis in immunocompromised patients N Engl J Med 367 2012 2126 2132
120. A.M. De Palma, I. Vliegen, E. De Clercq, and J. Neyts Selective inhibitors of picornavirus replication Med Res Rev 28 2008 823 884
121. K.O. Chang, and D.W. George Interferons and ribavirin effectively inhibit Norwalk virus replication in replicon-bearing cells J Virol 81 2007 12111 12118 (Pubitemid 350085826)
122. A.A. van de Ven, J.W. Douma, C. Rademaker, A.M. van Loon, A.M. Wensing, J.J. Boelens, E.A. Sanders, and J.M. van Montfrans Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia Antivir Ther 16 2011 611 614
123. J. Rocha-Pereira, R. Cunha, D.C. Pinto, A.M. Silva, and M.S. Nascimento (E)-2-styrylchromones as potential anti-norovirus agents Bioorg Med Chem 18 2010 4195 4201
124. J. Rocha-Pereira, D. Jochmans, K. Dallmeier, P. Leyssen, M.S. Nascimento, and J. Neyts Favipiravir (T-705) inhibits in vitro norovirus replication Biochem Biophys Res Commun 424 2012 777 780
125. J. Rocha-Pereira, D. Jochmans, K. Dallmeier, P. Leyssen, R. Cunha, and I. Costa Inhibition of norovirus replication by the nucleoside analogue 2'-C-methylcytidine Biochem Biophys Res Commun 427 2012 796 800
126. V.P. Costantini, T. Whitaker, L. Barclay, D. Lee, T.R. McBrayer, and R.F. Schinazi Antiviral activity of nucleoside analogues against norovirus Antivir Ther 17 2012 981 991
127. L. Coelmont, J. Paeshuyse, M.P. Windisch, E. De Clercq, R. Bartenschlager, and J. Neyts Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine Antimicrob Agents Chemother 50 2006 3444 3446 (Pubitemid 44527521)
128. E. Mastrangelo, M. Pezzullo, D. Tarantino, R. Petazzi, F. Germani, and D. Kramer Structure-based inhibition of Norovirus RNA-dependent RNA polymerases J Mol Biol 419 2012 198 210